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Objective: Although the results of aortic valve replacement with different valve prostheses are well documented
in terms of survival, the risks of (valve-related) events are less well explored.
Methods:We used a dataset of 3934 patients who underwent aortic valve replacement with either a bioprosthesis
(73%) or a mechanical prosthesis (27%) between 1982 and 2003 to simulate the outcome of patients after aortic
valve replacement with either valve type. With the use of microsimulation, we compared total age and gender-
specific life expectancy, event-free life expectancy, reoperation-free life expectancy, lifetime risks of reoperation,
and valve-related events for both valve types.
Results: The total follow-up was 26,467 patient-years. The mean follow-up was 6.1 years in the biological arm
and 8.5 years in the mechanical arm. The mean age at implantation was 70 and 58 years for biological and me-
chanical prostheses, respectively, and the percentage of concomitant coronary artery bypass grafting was 47%
and 28%, respectively. For a 60-year-old man, simulated life expectancy in years for biological versus mechan-
ical prostheses was 11.9 versus 12.2, event-free life expectancy was 9.8 versus 9.3, and reoperation-free life ex-
pectancy was 10.5 versus 11.9. Lifetime risk of reoperation was 25% versus 3%. Lifetime risk of bleeding was
12% versus 41%.
Conclusion: Even for patients aged 60 years, event-free life expectancy is better with a bioprosthesis. Although
the chance of reoperation is higher, the lifetime risk of bleeding is lower compared with a mechanical prosthesis.
Comparing lifetime event risks between different types of valve prostheses provides more insight into patient out-
come after aortic valve replacement and aids patient selection and counseling.
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Biological and mechanical valve prostheses are the most
commonly used valve substitutes for replacement of the na-
tive aortic valve. Each valve type has its own advantages and
drawbacks. The risk of reoperation for structural valve dete-
rioration (SVD) in patients with a biological valve increases
with time and decreases with advancing age. In contrast,
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coagulation, and the risk of bleeding events increases with
advancing age.
Outcome after aortic valve replacement (AVR) with ei-
ther valve type is well documented in the literature. These
results are mostly described in terms of cumulative survival,
freedom from events and reoperation, and linearized occur-
rence rates of valve-related complications and their conse-
quences. A patient’s lifetime risk of having a (valve-related)
event after AVR is less well explored. Estimations of survival
and valve-related event risk for an individual patient after
AVR are difficult to determine using standard time-to-event
analyses.1 Nevertheless, these parameters are important in
counseling a patient. The goal of this study was to calculate
detailed and age-specific patient outcome afterAVRwithme-
chanical and biological prostheses by using microsimulation.
MATERIALS AND METHODS
Patients
A report on a large single-center dataset on outcome after AVR from
Vancouver, Canada, was published using standard methods of data analy-
sis.2 For the input of the microsimulation model, we used essentially the
same primary dataset but excluded reoperations and operations with con-
comitant procedures other than coronary artery bypass grafting, leaving
3934 primary AVR procedures. Table 1 summarizes the dataset.ardiovascular Surgery c Volume 137, Number 4 881
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AVR ¼ aortic valve replacement
CAD ¼ coronary artery disease
SVD ¼ structural valve deterioration
Methods
A microsimulation model was used to simulate the lives of patients after
AVR. A microsimulation model is a computer model that simulates a repre-
sentative population at the individual patient level. This simulation model
offers a complementary tool to standard methods of outcome analysis by
simulating the lives of virtual patients until death and taking into account
all complications that may occur over time (including repeating events,
changing hazards over time, or with the occurrence of prior events). The
model can provide insight into age- and sex-specific life expectancy and
gives detailed information on the lifetime risk of valve-related events. De-
tailed descriptions on how to construct, test, and run this model have
been published.3-5 The model can be downloaded at www.cardiothoracicre-
search.nl.
Model input. The data needed to run the microsimulation model com-
prise the following: 1) occurrence of valve-related events and their outcome,
2) operative and reoperative mortality, 3) background mortality of the gen-
eral population, and 4) excess mortality. Valve-related events were defined
in accordance with the guidelines.6
1. By using the Vancouver dataset, we calculated occurrence rates of
valve-related events and their outcome (eg, death and reoperation) The re-
sults are shown in Appendix E1 (Table E2). For most events, linearized oc-
currence rates were calculated, but a Weibull function was constructed for
the occurrence of SVD. For bleeding, we assumed an age-dependent inci-
dence and mortality, described below.
The cumulative risk of SVD in a bioprosthesis decreases with increasing
age of the patient at valve implantation and increases subexponentially with
time elapsed since implantation.7 Grunkemeier and colleagues8 and Tho-
man and colleagues9 have shown that theWeibull distribution, a generaliza-
tion of the exponential distribution, is efficient in summarizing SVD in
biological valves. The formula for the hazard of SVD is: h(t) ¼ e-(t/s)^b.
On the basis of the Vancouver dataset, we estimated the parameters of
this distribution. The value of the scale (s) parameter of the Weibull model
was fitted to represent SVD and depended on age: s ¼ e 2.209þ 0.0153 * age.
The shape parameter (b), which reflects the changing risk over time, was
estimated at 3.211.
The incidence risk of bleeding increases with advancing age, especially
in patients with a mechanical valve who require lifelong anticoagulation.
The occurrence of bleeding in the biological group was modeled as an
age-dependent hazard of 0.076 with an age-dependent mortality of
0.0345.10 For the mechanical group, a Gompertz distribution was used
(g ¼ 0.076; l ¼8.71).11
Because the risk of prosthetic valve endocarditis early after valve re-
placement is higher than later on, 2 phases of constant risks were used for
prosthetic valve endocarditis. The linearized occurrence rate of the first
phase, until 6 months after AVR, has an odds ratio of 5.8 for mechanical
bioprostheses and 6.7 for biological bioprostheses compared with the sec-
ond phase. These numbers are obtained from an earlier meta-analysis.12
The linearized occurrence rate of the second period was derived from the
Vancouver dataset.
2. Operative mortality was calculated as 2.7% for a 40-year-old man, in-
creasing with an odds ratio of 1.034 for age (per year).11 This corresponds to
a 5.0%mortality for a 60-year-old man. For each reoperation, an additional
odds ratio of 1.7 was used.4,12-14 This odds ratio corresponds with the odds
ratio of 1.6 that the STS risk calculator15 and Rankin and colleagues16 used
to calculate the risk of primary versus secondary AVR.882 The Journal of Thoracic and Cardiovascular Su3. The background mortality, which is the mortality experienced by the
normal population, is the equivalent of the life expectancy in the normal
population. This was calculated using age- and sex matched American
life tables derived from the Vital Statistics of the United States 1992,
from the Centers for Disease Control and Prevention and the National Cen-
ter for Health Statistics.17 The life expectancy curves of the normal Amer-
ican, British Columbian, and United Kingdom male populations are shown
in Figure 1,17-19 which also displays the microsimulation-calculated life
expectancy after AVR.
4. The excess mortality is the mortality difference between the general
population and patient population that cannot be accounted for by valve-re-
lated events but can be ascribed to increased occurrence of sudden death,
underreporting of valve-related events, and underlying pathology such as
left ventricular hypertrophy.13,20 The hazard ratios after AVR are previously
estimated as 2.9, 1.8, 1.2, and 0.8 for male patients aged 45, 55, 65, and 75
years, respectively.12
Model validation. To assess the validity of the microsimulation
model predictions, the microsimulation-calculated survival for patients
with mechanical or biological prostheses was compared with the observed
survival in the Vancouver dataset (internal validation). For external valida-
tion of the biological valve simulations, a dataset from Portland, Oregon,
was used.21 The simulations of the mechanical valves were validated by
comparison with a dataset on patients with mechanical valves in the United
Kingdom Heart Valve Registry.22
Sensitivity analysis. One-way sensitivity analysis was performed to
study the effect of changing one of the input parameters on model outcome
(eg, life expectancy, event-free life expectancy, reoperation-free life expec-
tancy, and lifetime risk of events). The baseline estimates of the valve-re-
lated events were varied by 25% to obtain favorable and unfavorable
outcomes for a 60-year-old man after AVR.
RESULTS
As shown in Figure 1, life expectancy after AVR is com-
parable for biological and mechanical prostheses for patients
among all studied ages. Also, life expectancy after AVR is
substantially lower than the life expectancy of the general
population, especially in the younger age groups. Life ex-
pectancy of the normal population differs between different
TABLE 1. Summary dataset description
Bioprosthesis
Mechanical
prosthesis
No. of patients 2860 1074
Percentage of total dataset 72.7 27.3
Follow-up (patient-y) 17,352 9,115
Mean follow-up (y) 6.1 8.5
Mean age (y) 70.0 57.6
Male (%) 65.7 71.4
CABG (%) 47.3 27.7
Atrial fibrillation (%) 7.0 9.7
Prosthesis brands (%)
Carpentier-Edwards supra-annular valve
porcine (Irvine, Calif)
56.5 0
Carpentier-Edwards Perimount pericardial 23.0 0
Medtronic Mosaic porcine (Minneapolis,
Minn)
20.5 0
St Jude Medical (St Paul, Minn) 0 53.3
CarboMedics Inc (Austin, Tex) 0 46.7
CABG, Coronary artery bypass grafting.rgery c April 2009
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FIGURE 1. Life expectancy in men of different ages in British Columbia (BC), Canada, the United Kingdom (UK), and the United States (US) versus life
expectancy after AVR in British Columbia and the United States. LE, Life expectancy; MP, mechanical prosthesis; BP, biological prosthesis.A
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The differences in life expectancy between these countries
disappear with increasing age.
The lifetime risk of reoperation is higher in patients with
bioprostheses than in patients with mechanical valves, but
the anticoagulation-related bleeding risk is higher in patients
with mechanical prostheses (Figure 2). The risk of a bleeding
event in the bioprosthesis group is approximately 12% in
a 60-year-oldman. The lifetime risk of reoperation in the me-
chanical group is approximately 3% in a 60-year-old man.
For patients aged more than 60 years of age, event-free
life expectancy is better with a bioprosthesis (Figure 3),
mainly because lifetime bleeding risk is lower. As shown
in Figure 2, at age 60 years, the bleeding risk in patients
with a mechanical prosthesis is already higher than the reop-
eration risk would be if a patient of the same age received
a bioprosthesis. Please note that in the Vancouver dataset,
the observed mortality after a bleeding event was 22%. In
contrast, the mortality after a reoperation for SVD (n ¼ 137)
was 7.3%. The mean age of this patient group was 54 years.
Internal Validation
Figure E1, A presents the overall observed survival for
patients with bioprostheses or mechanical prostheses in the
Vancouver dataset versus the simulated survival of male pa-
tients aged 70 years with a bioprosthesis and patients aged
58 years with a mechanical prosthesis. These are the mean
ages of the respective groups. Figure E1, B and C present
the internal validation subdivided for each age group for
biological and mechanical valves, respectively. Although
validation appears adequate for the average patient in the
dataset, a systematic underestimation of survival was ob-
served in the simulated survival output, particularly in the
subgroups of older patients with mechanical valves.
External Validation
Figure E2, A depicts the external validation of survival of
patients with a bioprosthesis. Figure E2, B describes the ex-
ternal validation of the survival of patients with a mechanical
prosthesis.The Journal of Thoracic andSensitivity Analyses
Tables E2 and E3 shows the summary of the 1-way sen-
sitivity analysis for bioprostheses and mechanical prosthe-
ses. Variation of the input parameters of the model yielded
only relatively small changes in the output, except for
changes in the hazard ratios for excess mortality and to
a lesser extent changes in median time to SVD. Changing
background populations has an effect on the event free
life-expectancy estimates which is shown in Figure E3, A.
The level of uncertainty of the age cut-off point at which
a bioprosthesis is preferable over a mechanical prosthesis
is displayed in Figure E3, B.
DISCUSSION
The estimates of lifetime patient risk of nonfatal events
are obtained using cumulative incidence analysis. Some-
times Kaplan–Meier analysis is incorrectly used for this
purpose. The issue of the appropriate use of actuarial (Ka-
plan–Meier) and actual analyses has been highlighted in sev-
eral publications.23,24 For the present article the differences
in results with either analysis are illustrated in Figure E4.
Actuarial analysis of all-cause reoperation in the Vancouver
bioprosthesis group would give a cumulative risk estimate of
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dence (‘‘actual’’) value, which is 16% at 15 years.
Total life expectancy after AVR is not different whether
the patient receives a mechanical valve or a bioprosthesis.
Because reoperation-free life expectancy, event-free life ex-
pectancy, and lifetime event risks do differ between both pa-
tient groups, these are more important factors in choosing
which valve substitute should be implanted in a particular
patient.
For patients aged more than 60 years, event-free life ex-
pectancy is better with a bioprosthesis, mainly because the
risk of bleeding with a bioprosthesis is lower compared
with a mechanical valve. Of course this is at the cost of
the higher risk of a reoperation for SVD. However, the life-
time risk of a reoperation for a 60-year-old man in whom
a biological valve is implanted is only 25% (risk of reoper-
ation because of SVD is 22%), so three quarters of the 60-
year-old patients will never experience a reoperation. The
lifetime risk of a bleeding event when the same patient
would have a mechanical valve implanted is as high as
41%. The overall observed mortality of a bleeding event
in the Vancouver dataset was 22%, which implies that these
bleedings are life-threatening events. In contrast, the mortal-
ity risk after reoperation for SVD was 7.3% in this dataset,
certainly not negligible but far lower than the mortality of
bleeding. This is in accordance with an earlier report on
the same dataset.25
As can be seen in Table 1, coronary artery disease (CAD)
occurs more frequently in the bioprosthesis group, probably
because the mean age is higher. Previous publications have
shown that performing additional coronary artery bypass
grafting does not have a significant impact on the crossing
points of the life expectancy and event-free life expectancy
curves.26 Patients who have CAD have a shorter life expec-
tancy than those without CAD. Because of this shorter life
expectancy, both the lifetime risk of a reoperation in the bio-
prosthesis group and the lifetime risk of bleeding and throm-
boembolic events in the mechanical group are lower
compared with patients without CAD. The end result is884 The Journal of Thoracic and Cardiovascular Suthat the age cutoff point at which a bioprosthesis is prefera-
ble over a mechanical prosthesis does not change and there-
fore does not affect prosthetic valve selection.
The American College of Cardiology/American Heart
Association guidelines generally recommend implantation
of a bioprosthesis for patients aged more than 65 years.27
Guided by the simulation data presented in this study, pa-
tients in younger age groups, even at approximately 60 years
of age, may benefit more from a biological prosthesis than
a mechanical prosthesis. This is in agreement with the report
by Chan and colleagues,2 which is based on a standard
analysis of the same patient population. Newer biological
prostheses may show more reduction in the need for
reoperation for SVD and thus lower the threshold for im-
plantation of a bioprosthesis more.
To reduce bleeding complications, more emphasis should
be put on new anticoagulation strategies, new mechanical
valve prostheses that require lower international normalized
ratio target rate, or lowering the age threshold for implanta-
tion of a bioprosthesis. The negative aspect of lowering this
threshold is that not only more patients but also older pa-
tients will require a reoperation. This of course may increase
the reoperative mortality. On the other hand, new less-inva-
sive techniques to replace the aortic valve are rapidly emerg-
ing in cardiothoracic fields. The first reports on percutaneous
and transapical approaches to replace the aortic valve are
promising, and their use is expected to increase.28,29 Al-
though experience with these techniques is rather limited
and each approach seems to have its own advantages and
disadvantages, their potential is not limited to treat native
aortic valve disease. Most likely these techniques are also
applicable to replace deteriorated biological prostheses, the
‘‘valve-in-valve’’ concept.30 This could reduce operative
morbidity and mortality in high-risk subsets of patients
and may therefore offer a solution for the treatment of el-
derly patients who experience SVD. In contrast, currently
it seems the awareness of surgeons that SVDmay occur after
implantation of a biological valve is far greater than the
awareness of the incidence and impact of bleeding eventsrgery c April 2009
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edge may affect the valve selection process.
Limitations
Microsimulation is capable of accurate and precise simu-
lations, as long as the input of the model is based on signif-
icantly large and, more important, high-quality datasets. The
quality of the model output is directly dependent on the
quality of the input. The data to feed microsimulation
models are usually derived from historical cohorts with
a considerable follow-up and may not necessarily be appli-
cable to 21st century practice. For instance, the mean age of
the patients who underwent reoperation is low, which
implies the patients were young when they received their
biological valves, reflecting surgical practice in the 1980s.
Currently, few young patients receive a bioprosthesis.
Also, the age-specific operative mortality estimates by the
model are based on previous meta-analyses performed sev-
eral years ago, and at the moment these estimates seem high.
Perhaps new estimates should be established, although the
effect of operative mortality on long-term outcome and
life expectancy is only small, as can be seen in the sensitiv-
ity analyses (Tables E2 and E3). Further, it can be argued
that current valve prostheses have the same occurrence rates
as prosthetic valves that were implanted in the past. It is pos-
sible that rates are lower now. Despite this drawback, the
Vancouver database consists of high-quality data on an ex-
tensive number of patients who were interviewed by annual
telephone calls and whose medical records (including echo-
cardiograms) were reviewed to check if any events had oc-
curred. In doing so, it is likely that not many events have
been missed.
More high-quality datasets are needed to incorporate
other variables than only age and sex. Other determinants
of life expectancy after AVR are coexisting CAD; left ven-
tricular, pulmonary, and renal function; and other comor-
bid conditions such as malignancies or neurologic
diseases. If these parameters were taken into account, the
model would represent survival more tailored to the indi-
vidual patient.
For nowwe can only perform a 1-way sensitivity analysis.
It would be better to check the results in simulated outcome
when the distributions of the input parameters are known. In
this matter, work is in progress.
Microsimulationmodels are not yetwidely knownandused
in the cardiothoracic fields, and they are not available in stan-
dard statistical software packages yet. The model described in
this article is available by downloading the program along
with instructions at www.cardiothoracicresearch.nl.
CONCLUSIONS
On the basis of the Vancouver dataset, it seems that even
for patients aged 60 years who require AVR, the implanta-
tion of a bioprosthesis generally may be considered superiorThe Journal of Thoracic andover a mechanical prosthesis. The risk of bleeding with a bi-
oprosthesis is not absent, but compared with mechanical
valves, the risk reduction of bleeding that can be achieved
with a bioprosthesis outweighs the increased risk associated
with SVD.
Comparing lifetime event risks between different types of
valve prostheses provides more insight into patient outcome
after AVR and aids in patient selection and counseling.
When combined with careful assessment of individual pa-
tient preferences, this will provide a new key to optimized
informed decision making.
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Appendix E1.
Internal Validation
The overall survival that was calculated by the model
showed a slightly worse survival for both prosthesis groups
than observed in the Vancouver dataset (Figure E1, A).
When this dataset is split by different age groups, the differ-
ences between simulated and observed survival increase, es-
pecially in the older ages and more in the mechanical group
than in the biological group (Figure E1, B and C). Appar-
ently the excess mortality is lower in the Vancouver dataset
than it is in our model. An explanation may be that the mi-
crosimulation model predicts life expectancy a priori in
a random patient, only knowing age and sex. The assump-
tion is made that the excess mortality is equal for both pa-
tients who receive mechanical or bioprostheses. However,
in clinical practice other patient characteristics are also taken
into account in the valve selection process; patients with
a better life expectancy are more likely to receive a mechan-
ical valve, and patients with a decreased life expectancy are
more likely to receive a bioprosthesis. This patient selection
process is probably responsible for the differences between
observed and simulated survival.
External Validation
Although simulated survival after AVRwith a bioprosthe-
sis corresponded with the Portland dataset (Figure E2, A),
the simulated survival for the mechanical prostheses was
again lower than the observed survival in the UK Heart
Valve Registry (Figure E2, B). The differences between
the curves are considerable. Several factors can be responsi-
ble for this. First, patient selection is probably different
among medical centers, countries, and continents. Second,
prosthesis types and brands will differ between medical cen-
ters, but it is questionable whether this factor contributes
much to the observed survival differences. Third, back-
ground mortality is different between different countries.
This clearly influences life expectancy after AVR, as is
shown in Figure 1. However, difference in background mor-
tality has hardly any influence on the point of indifference
for the event-free life expectancy curves for both prostheses.
To show this, we simulated patients after AVR using both
background mortalities from the United States and British
Columbia, Canada. The effect on event-free life expectancy
is displayed in Figure E3, A. The curves will only shift up-
ward or downward, but the age cutoff point at which a bio-
prosthesis is preferable over a mechanical prosthesis remains
the same. This finding implies that the conclusions drawn
from this article would remain the same for patients from
British Columbia or patients from other Western countries,
such as the United Kingdom. Figure E3, B is a detail of Fig-
ure 3 and Figure E3, A and displays the crossing point of the
event-free life expectancy curves. The 68% confidence
limits around the event-free life expectancy curves of the
mechanical and bioprosthesis groups are also given The
crossing 68% confidence limits demarcate the area in which
the real crossing point of the event-free life expectancy
curves lies (with a 95% certainty).
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FIGURE E1. Internal validation. A, Simulated survival of 58-year-old patients who received mechanical bioprostheses and 70-year-old patients who re-
ceived bioprostheses versus total observed survival in the biological and mechanical prostheses groups of the Vancouver dataset. B, Simulated survival of
55-, 65-, and 75-year-old male patients with a bioprosthesis versus the bioprosthesis group of the Vancouver dataset, subdivided in age categories. C, Sim-
ulated survival of 55-, 65-, and 75-year-old male patients with a mechanical prosthesis versus the mechanical prosthesis group of the Vancouver dataset, sub-
divided in age categories. MP, mechanical prosthesis; BP, biological prosthesis.
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FIGURE E2. External validation. A, Simulated survival of 55-, 65-, and 75-year-old male patients with a bioprosthesis versus the observed survival in the
Portland dataset, subdivided in age categories. B, Simulated survival of 55-, 65-, and 75-year-old male patients with a mechanical prosthesis versus the
observed survival in the United Kingdom Heart Valve Registry mechanical dataset, subdivided in age categories. UKHVR, United Kingdom Heart Valve
Registry.
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FIGUREE3. Event -free life expectancy for men at different ages of valve implantation. A, Event-free life expectancy for menwith a mechanical valve (solid
lines) versus a bioprosthesis (dotted lines). Black lines represent the United States population; grey lines represent the population in British Columbia, Canada.
Background mortality changes among different populations, which has an effect on absolute event-free life expectancy but hardly any effect on the age cutoff
point at which a bioprosthesis is preferable over a mechanical prosthesis. B, Detail of Figures 3 and E3, A. The crossing points of the 68% confidence limits
around the event-free life expectancy curves demarcate the area in which the real event-free life expectancy age cutoff point lies (with a 95% certainty).MP,
Mechanical prosthesis; BP, biological prosthesis. EFLE, event-free life expectancy.
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FIGURE E4. Actual versus actuarial analysis of all-cause reoperation and reoperation for SVD in the biological group of the Vancouver dataset. SVD,
Structural valve deterioration.
Acquired Cardiovascular Disease van Geldorp et al
886.e4 The Journal of Thoracic and Cardiovascular Surgery c April 2009
A
C
D
TABLE E1. Input microsimulation model, directly derived from the Vancouver dataset
n
Linearized
occurrence ratea
Fatalities if no
reoperationb
Mortality
rate
No. of
reoperations
Reoperation
ratec
Valve-related event BP MP
BP (17,352
patient-y)
MP (9115
patient-y) BP MP BP MP BP MP BP MP
Bleeding 92 202 0.53 Gompertz 34 33 0.37 0.16 0 0 0 0
Nonstructural
dysfunction
40 41 0.23 0.45 2 4 0.05 0.10 35 16 0.92 0.43
Prosthetic valve
endocarditis (late)
53 (46) 16 (7) 2 periods
(0.29)
2 periods
(0.082)
18 1 0.34 0.06 20 9 0.57 0.60
SVDd 137 0 Weibull 0 0 NA 0 NA 137 NA 1.0 NA
Thromboembolism 219 121 1.26 1.33 72 28 0.33 0.23 0 0 0 0
Valve thrombosis 7 5 0.04 0.06 0 1 0 0.20 7 2 1.0 0.50
Sudden unexpected
Unexplained deathe
15 7 NA NA NA NA NA NA NA NA NA NA
Total 585 392 126 67 199 27
BP, Biological prosthesis;MP, mechanical prosthesis; SVD, structural valve deterioration; NA, not available. aLinearized occurrence rate: number of events per 100 patient-years.
bNumber of fatalities if no reoperation was performed (either because patient died before or after decision not to operate). cProportion who underwent reoperation after surviving the
event in the first place (no. reoperations/[no. events—no. fatalities]). dSVDwas defined as ‘‘reoperation because of SVD’’ and therefore has no direct fatalities. eThe cases of sudden
unexpected unexplained death were entered into the model as part of the ‘‘excess mortality.’’
TABLE E2. Sensitivity analysis for a 60-year-old American man after aortic valve replacement with a bioprosthesis
Input Output
Valve-related
event
Linearized
occurrence
rate
(baseline)
Linearized
occurrence
rate25%
(favorable)
Linearized
occurrence
rateþ25%
(unfavorable)
Life
expectancy
Event-free life
expectancy
Reoperation-free life
expectancy
Favorable Unfavorable Favorable Unfavorable Favorable Unfavorable
Bleeding 0.53 0.40 0.66 12.1 11.9 9.9 9.7 10.6 10.5
Nonstructural
dysfunction
0.23 0.17 0.29 12.1 12.1 9.9 9.8 10.7 10.6
Prosthetic valve
endocarditis
0.29 0.22 0.36 12.2 12.1 9.9 9.8 10.7 10.6
SVDa 22.0 27.5 16.5 10.6 10.3 9.3 8.4 10.0 8.9
Thromboembolism 1.26 0.95 1.58 12.2 12.0 10.1 9.6 10.7 10.6
Valve thrombosis 0.04 0.03 0.05 12.1 12.1 9.9 9.9 10.7 10.6
Operative mortality 5.0% 3.8% 6.3% 12.1 11.8 9.9 9.6 10.7 10.4
Hazard ratio 1.2 0.9 1.5 12.9 11.3 10.3 9.4 11.2 10.1
SVD, structural valve deterioration. aMedian time to SVD is 22.0 years.
TABLE E3. Sensitivity analysis for a 60-year-old American man after aortic valve replacement with a mechanical prosthesis
Input Output
Valve-related
event
Linearized
occurrence
rate
(baseline)
Linearized
occurrence
rate25%
(favorable)
Linearized
occurrence
rateþ25%
(unfavorable)
Life
expectancy
Event-free life
expectancy
Reoperation-free life
expectancy
Favorable Unfavorable Favorable Unfavorable Favorable Unfavorable
Bleeding Gompertz 12.9 8.7 11.0 4.1 12.6 8.5
Nonstructural
dysfunction
0.45 0.34 0.56 12.2 12.2 9.3 9.2 12.0 11.9
Prosthetic valve
endocarditis
0.08 0.06 1.0 12.2 12.2 9.3 9.2 12.0 11.9
SVD NA NA NA NA NA NA NA NA NA
Thromboembolism 1.33 1.00 1.66 12.3 12.1 9.5 9.1 12.0 11.9
Valve thrombosis 0.06 0.04 0.07 12.2 12.2 9.3 9.3 12.0 11.9
Operative mortality 5.0% 3.8% 6.3% 12.1 11.8 9.9 9.6 10.7 10.4
Hazard ratio 1.2 0.9 1.5 12.9 11.4 9.7 8.8 12.7 11.2
SVD, Structural valve deterioration; NA, not available.
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